Neuropsychopharmacology Reports最新文献

{"title":"Long-Term Impact of EGUIDE Training on Facility-Wide Guideline Adherence Rate in Schizophrenia and Major Depressive Disorder-A Methodological Reflection.","authors":"Ghufran Saeed Rizvi","doi":"10.1002/npr2.70103","DOIUrl":"10.1002/npr2.70103","url":null,"abstract":"<p><p>This Letter highlights crucial methodological flaws, including selection bias and ignored data clustering, in the EGUIDE training impact study. We recommend adopting quasiexperimental designs, multilevel modeling, and patient-centered outcomes to ensure future research accurately confirms the program's true clinical effectiveness.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70103"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12933874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147284533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Amelioration of Adults' Mental Health Conditions and Symptoms Through Spiritual Energy Therapy: Randomized Controlled Trial.","authors":"","doi":"10.1002/npr2.70099","DOIUrl":"10.1002/npr2.70099","url":null,"abstract":"<p><strong>Retraction: </strong>M. K. Trivedi, A. Branton, D. Trivedi, S. Mondal and S. Jana, \"Amelioration of Adults' Mental Health Conditions and Symptoms Through Spiritual Energy Therapy: Randomized Controlled Trial,\" Neuropsychopharmacology Reports 45, no. 3 (2025): e70050, https://doi.org/10.1002/npr2.70050. The above article, published online on 10 September 2025 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Tsuyoshi Miyakawa; The Japanese Society of Neuropsychopharmacology; and John Wiley & Sons Australia, Ltd. The retraction has been agreed upon as a similar version of this article by the same authors was previously retracted by the Journal of General and Family Medicine (https://doi.org/10.1002/jgf2.773). Although revisions have been made, the article does not adequately address the previously identified concerns. In particular, issues regarding the appropriateness of the control group and the psychological questionnaire scoring method remain unresolved. Additionally, some biomarker values remain implausible without sufficient justification and claims regarding the efficacy of spiritual energy therapy continue to lack independent supporting evidence. The editors agree the results and conclusions are unreliable. The authors disagree with the retraction.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70099"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Lacosamide in the Treatment of Delirium Complicated With Ileus: Four Cases.","authors":"Shinji Sato","doi":"10.1002/npr2.70102","DOIUrl":"10.1002/npr2.70102","url":null,"abstract":"<p><p>Delirium is a common disease in elderly patients and requires medications, although nondrug interventions are recommended. When delirious patients are complicated with ileus, the selection of drugs would be difficult. In this paper, three cases of antipsychotic-induced paralytic ileus successfully managed with lacosamide are presented without any severe adverse effects, including psychiatric symptoms. Lacosamide is a newer antiepileptic drug that acts on the sodium channels. Drug-induced eruptions are rare compared to other antiepileptics, such as carbamazepine and lamotrigine. Lacosamide can be administered intravenously as well as orally. The mechanisms of ileus have been suggested; to involve antagonism of the cholinergic, histaminergic, and serotonergic systems. Since lacosamide is not related to these antagonists, it may be one of the helpful options for treating delirium tremens in elderly patients.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70102"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12927998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146258800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Pregnancy Hope and Premenstrual Dysphoric Disorder Among Female Workers: A Cross-Sectional Online Survey in Japan.","authors":"Yuka Ito, Natsu Sasaki, Yoshiaki Kanamori, Rikako Tsuji, Mako Iida, Kazuhiro Watanabe, Miho Egawa, Daisuke Nishi","doi":"10.1002/npr2.70106","DOIUrl":"10.1002/npr2.70106","url":null,"abstract":"<p><strong>Objectives: </strong>This cross-sectional study examined the association between pregnancy hope and premenstrual dysphoric disorder (PMDD) outcomes among full-time working women.</p><p><strong>Methods: </strong>We analyzed an October 2023 survey of nulligravid women aged 20-44 years (N = 1947). PMDD diagnosis and symptom severity were assessed using a DSM-IV-based scale. Logistic and linear regression examined associations with pregnancy hope and tested interaction by marital status.</p><p><strong>Results: </strong>PMDD prevalence was 5.4% with pregnancy hope and 4.8% without. Pregnancy hope was not associated with PMDD diagnosis (crude OR = 1.13, 95% CI: 0.71-1.80) and remained null after adjustment. Pregnancy hope was weakly associated with higher symptom scores (crude standardized β = 0.059, p = 0.009), persisting after adjustment. Interaction by marital status was not significant.</p><p><strong>Conclusion: </strong>Among full-time workers, pregnancy hope was unrelated to PMDD diagnosis but was weakly associated with subthreshold symptom severity. Longitudinal studies that comprehensively assess multidimensional pregnancy intention, perceptions of menstruation, and work-related constraints are needed to clarify causal directionality and mechanisms.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70106"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Drug Stigma Scale Among Community Pharmacists Concerning Individuals Who Use Over-The-Counter Drugs.","authors":"Munenori Katayama, Takuya Shimane, Norihito Shirakawa, Kanna Sugiura, Ken Inada, Jun Konishi, Yoshihito Sakurai, Keiji Kobara, So Fujishiro, Toshihiko Matsumoto","doi":"10.1002/npr2.70101","DOIUrl":"10.1002/npr2.70101","url":null,"abstract":"<p><strong>Aim: </strong>Stigma among pharmacists toward individuals who use over-the-counter (OTC) drugs for unintended purposes may hinder effective support. This study aimed to assess the psychometric properties of the Drug Stigma Scale (DSS) when applied to pharmacists and to examine the factors associated with stigma levels in this context.</p><p><strong>Methods: </strong>A survey was anonymously distributed to pharmacists attending voluntary online workshops organized by a prefectural pharmaceutical association in Japan from August 2023 to March 2024. These workshops focused on OTC drug use for unintended purposes and the gatekeeping role of pharmacists. A total of 490 responses were analyzed. The DSS, originally a 24-item scale developed for the Japanese context, was adapted to specify \"OTC drug use.\" Confirmatory factor analysis (CFA) and internal consistency analyses were conducted. Concurrent validity was assessed using correlations and group comparisons based on demographic variables, confidence in knowledge, and gatekeeper self-efficacy (GKSES).</p><p><strong>Results: </strong>The adapted 18-item structure of the DSS demonstrated a good model fit (CFI = 0.93, TLI = 0.91, GFI = 0.92, RMSEA = 0.061). Internal consistency ranged between α = 0.68 and 0.88. Female pharmacists scored significantly lower on several subscales than male pharmacists, indicating less stigmatizing attitudes. Additionally, lower DSS scores were observed among pharmacists who had frequent contact with individuals who misuse OTC drugs, had a family history of such misuse, or sought help for related issues. The correlations between the DSS and GKSES scores were weak but significant.</p><p><strong>Conclusion: </strong>The DSS is a valid tool for measuring stigma among pharmacists concerning OTC drug use. The findings suggest that direct or familial experiences with OTC drug misuse may reduce stigmatized attitudes. Efforts to reduce stigma should extend beyond knowledge-based interventions and consider community engagement and opportunities for pharmacists to hear individuals' lived experiences.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70101"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Response to \"Concerns Regarding Masataka et al.'s 'Revisiting the Gateway Drug Hypothesis for Cannabis'\".","authors":"Yuji Masataka, Toshihiko Matsumoto","doi":"10.1002/npr2.70093","DOIUrl":"10.1002/npr2.70093","url":null,"abstract":"<p><p>We clarify Dr. Narita's concerns by replacing subjective wording with data-based statements, emphasizing the descriptive-not causal-nature of our analysis, and noting that logistic regression was exploratory. Our findings show both progression and non-progression pathways, indicating no single dominant gateway pattern among Japanese cannabis users.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70093"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12892117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Anti-Zic4 Antibody-Positive Cerebellar Degeneration Following COVID-19 Infection.","authors":"Risa Suzuki-Yamamoto, Asuka Nakajima, Tsuyoshi Furuya, Takahiro Koinuma, Atsuhito Fuse, Hiroto Eguchi, Yasushi Shimo","doi":"10.1002/npr2.70094","DOIUrl":"10.1002/npr2.70094","url":null,"abstract":"<p><strong>Background: </strong>Although anti-Zic4 antibodies are associated with paraneoplastic cerebellar degeneration, predominantly in small-cell lung carcinoma, their role in postinfectious autoimmunity remains poorly understood.</p><p><strong>Case report: </strong>Here, we report a 53-year-old woman who developed progressive cerebellar degeneration following coronavirus disease 2019 (COVID-19), characterized by isolated anti-Zic4 antibody positivity in the absence of malignancy. Two months after developing mild respiratory symptoms, she developed dysarthria, imbalance, and gait ataxia. Neurological examination revealed gaze-evoked nystagmus, broad-based ataxia, and cerebellar dysmetria. Brain MRI demonstrated marked cerebellar atrophy, while cerebrospinal fluid analysis showed elevated protein, increased IgG index, and the presence of oligoclonal bands. Serological testing confirmed strong anti-Zic4 antibody positivity. Initial treatment with intravenous immunoglobulin and plasmapheresis achieved transient improvement and decreased antibody titers. However, 1 year later, recurrence of antibodies coincided with further cerebellar atrophy and posterior hypoperfusion on MRI and SPECT, despite maintenance immunotherapy with low-dose corticosteroids and periodic IVIG. Cognitive function was well preserved, highlighting the selective vulnerability of cerebellar circuits.</p><p><strong>Conclusion: </strong>This case illustrates an unusual phenotype of prolonged, isolated anti-Zic4 antibody-associated cerebellar degeneration triggered by SARS-CoV-2 infection, thus expanding the recognized clinical spectrum of Zic4-related disorders beyond paraneoplastic contexts. The underlying immunopathological mechanisms have yet to be elucidated. Notably, radiological progression was disproportionate to clinical stabilization, underscoring the necessity of long-term clinical/imaging surveillance. This case highlights the need for further studies to clarify pathophysiological links between COVID-19 and persistent autoimmune cerebellar degeneration.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70094"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12910518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence.","authors":"Tetsuo Nakabayashi, Kunihiro Iwamoto, Akiko Yamaguchi, Yuki Konishi, Momoe Saji, Reiji Yoshimura, Kousuke Kanemoto, Hirofumi Aoki, Masahiko Ando, Norio Ozaki","doi":"10.1002/npr2.70092","DOIUrl":"10.1002/npr2.70092","url":null,"abstract":"<p><p>The cross-national differences in automobile driving precautions stated in psychotropic drug package inserts primarily reflect regulatory policies and insufficient evaluation method standardization until recent years, rather than intrinsic ethnic differences. In January 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued the Criteria for Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance. These criteria were published as an appendix to an earlier guideline for evaluating these effects published in December 2022. These guidelines and criteria, developed by the authors, provide methods for evaluating the effects of psychotropic drugs. However, these are not intended to assess the fitness of an individual patient to drive. The MHLW guideline and criteria recommend a tiered approach for assessing clinically meaningful driving impairment. Adverse events affecting alertness, such as drowsiness, caused by psychotropic drugs on driving performance are more frequent during the initial treatment stages and dose escalation. Therefore, evaluating the effects of psychotropic drugs on driving performance requires careful consideration of the persistence of clinically meaningful impairment. Additionally, understanding the magnitude and duration of such effects is crucial for selecting appropriate treatments and offering effective guidance to patients. The MHLW criteria categorize the effects of psychotropic drugs on driving performance into four levels based on their magnitude and duration. Furthermore, the MHLW criteria could help to determine which clinical trials are necessary to evaluate the persistence of clinically meaningful impairment. Namely, the MHLW criteria could be used to structure the substantial evidence needed for evaluating the effects on driving performance for approval applications and clinical implementation.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70092"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12893847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146166094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catatonia an Unexpected Side Effect of Electroconvulsive Therapy: A Case Report.","authors":"Fatemeh Sheikhmoonesi, Behnam Abbasi, Tahoura Sedighi Barforoushi, Ebrahim Khoshnama","doi":"10.1002/npr2.70104","DOIUrl":"10.1002/npr2.70104","url":null,"abstract":"<p><strong>Introduction: </strong>Catatonia is a neuropsychiatric syndrome characterized by motor and behavioral abnormalities, often associated with severe psychiatric or medical conditions. The use of electroconvulsive therapy (ECT) is a well-established treatment for catatonia; however, paradoxical onset during treatment is rare.</p><p><strong>Case presentation: </strong>A 33-year-old woman with schizoaffective disorder, previously managed with antipsychotics, developed acute catatonia following the first ECT session. Her history included childhood epilepsy controlled with sodium valproate and long-term use of various antipsychotics, including clozapine. The patient developed stupor, mutism, and fixed staring immediately after ECT. All psychotropic medications were discontinued, and further ECT sessions were halted. The catatonia resolved within 24 h without further intervention. ECT was restarted after 7 days, leading to full remission after 15 sessions.</p><p><strong>Discussion: </strong>This case underscores the hypothesis of a rare paradoxical occurrence of catatonia induced by ECT, despite the absence of classic predisposing factors. The timing of catatonia suggests a potential interaction between ECT and other medications, particularly haloperidol, and the tapering of clozapine. This phenomenon warrants further investigation into the neurochemical mechanisms that might contribute to ECT-induced catatonia.</p><p><strong>Conclusion: </strong>The occurrence of catatonia following ECT in this case underscores the need for careful monitoring, particularly in patients with complex psychiatric histories or any risk factor for catatonia. Although this phenomenon is rare, clinicians should be aware of the potential for catatonia to develop even in the absence of typical risk factors and take steps to manage it promptly.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70104"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12949357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eight-Year Progression of Clinical Practice Implementation Following Guideline Training in the EGUIDE Project.","authors":"Kenta Ide, Kazuhiko Yamamuro, Hisashi Yamada, Naomi Hasegawa, Yusuke Arai, Hiroyuki Muraoka, Toru Horinouchi, Yasushi Kawamata, Shinichiro Ochi, Takashi Tsuboi, Junya Matsumoto, Naoki Hashimoto, Kazutaka Ohi, Numata Shusuke, Hikaru Hori, Ken Inada, Koichiro Watanabe, Norio Yasui-Furukori, Ryota Hashimoto","doi":"10.1002/npr2.70095","DOIUrl":"10.1002/npr2.70095","url":null,"abstract":"<p><strong>Aim: </strong>Clinical practice guidelines have improved the quality and standardization of psychiatric care; however, their long-term implementation in real-world settings remains limited. The Effectiveness of the Guidelines for Dissemination and Education (EGUIDE) project was established to promote sustained evidence-based practice through a multilayered educational program for psychiatrists in Japan.</p><p><strong>Methods: </strong>This multicenter observational study longitudinally tracked psychiatrists' self-rated clinical behavior (CB) scores related to guideline adherence for up to 8 years after initial EGUIDE participation. CB was assessed using a validated questionnaire covering general guideline use (CB-G), schizophrenia (CB-S), and major depressive disorder (CB-D), with a comprehensive index (CB-C) representing the mean of all domains. Data were analyzed using the Kruskal-Wallis test, the Mann-Whitney U test, and the Bonferroni correction (two-tailed p < 0.05).</p><p><strong>Results: </strong>A total of 1562 psychiatrists (mean age, 32.7 ± 7.1 years) were included. All CB indices (CB-C, CB-G, CB-S, and CB-D) significantly improved post training compared with the baseline (H = 831.2-984.0; all p < 10^-72), with small-to-moderate effect sizes (r = 0.09-0.29). These improvements were maintained throughout the 8-year follow-up, with no significant decline, and several domains showed small but continued increases between 3 and 7 years post training.</p><p><strong>Conclusion: </strong>The EGUIDE program achieved long-term, sustained improvements in psychiatrists' guideline-adherent clinical behaviors through an integrated system combining education, supervision, feedback, and follow-up. This autonomous, cyclical framework represents a high-impact model for continuous quality improvement and may be adaptable to other medical specialties.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 1","pages":"e70095"},"PeriodicalIF":1.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}